LOGIN  |  REGISTER
Cue Biopharma
Terns Pharmaceuticals

Phreesia Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection Assurance

November 08, 2023 | Last Trade: US$25.16 1.32 5.54

WILMINGTON, Del. / Nov 08, 2023 / Business Wire / Phreesia today announced its patient intake platform and data centers have earned certified status by HITRUST for information security.

We believe HITRUST Risk-based, 2-year (r2) Certified status demonstrates that Phreesia’s intake platform and data centers have met demanding regulatory compliance and industry-defined requirements and are appropriately managing risk. This achievement places Phreesia in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks, and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

“At Phreesia, we’re dedicated to upholding the highest security and compliance standards, and this recertification is a welcome recognition of those efforts” said Evan Roberts, Chief Operating Officer, Phreesia. “As we continue to grow and scale, we want our clients to be assured that we’re a trusted partner and responsible steward of their data. HITRUST certification gives them confidence that we take our commitment incredibly seriously.”

“HITRUST Certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST Certification is considered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,” said Jeremy Huval, Chief Innovation Officer, HITRUST. “Individually, each element exceeds most other programs, and collectively they make HITRUST Certification the most comprehensive, transparent, consistent, and highest quality assessment available.”

About Phreesia

Phreesia is a trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB